From Our Partners
Wednesday, June 29, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Chemical Threat Countermeasures Cooperative Research Projects

by Global Biodefense Staff
April 26, 2013

Laboratory ResearchThe National Institutes of Health has issued a funding opportunity announcement seeking grant applications for Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01s).

The mission of the CounterACT U01 program is to develop new and improved therapeutics for chemical threats to reduce mortality and morbidity during and after emergency events involving the release of chemical threat agents.

Chemical threat agents are toxic chemicals that could cause mass casualties after being released by a deliberate terrorist attack, or by industrial accident or natural disaster. The purpose of the U01 funding opportunity is to foster and support the development of Food and Drug Administration (FDA)-approved therapeutics that can be used effectively to treat individuals during a chemical emergency event.

The current effort only supports translational research which is clearly relevant to the development of therapeutics that will enhance medical response capabilities during a chemical emergency. The categories of research supported under this program may include:           

  • Mechanistic research to identify targets for therapeutic development
  • Creation and development of screening assays for therapy development
  • Creation and validation of animal models of chemical effects on humans
  • Identification of candidate therapeutics using primary/secondary screening efforts
  • Development of proof-of-principle data on the efficacy of candidate therapeutics
  • Advanced efficacy studies with appropriate animal models
  • Preliminary and advanced preclinical research including safety and pharmacokinetic studies

Letters of intent are due August 16, 2013. Further details are available under FOA Number: PAR-13-208.

From Our Partners
Tags: Animal Models

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC